Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Zenas, a clinical-stage biopharma, seeks a launch-experienced marketing leader to guide HCP branding for obexelimab from pre-launch through sustained post-launch performance. You will align with Sales, Strategic Engagement and agencies to translate insights into compliant, high-impact assets.
Partner with cross-functional teams to build capabilities as Zenas transitions to a fully commercial organization, delivering differentiated messaging and programs in the US market.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab's unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas' earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody.
We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence and Innovation - TRUE Innovation !
Zenas is seeking a collaborative, launch-experienced marketing leader to serve as the strategic brand leader for obexelimab among HCP audiences, including its first anticipated indication in IgG4-Related Disease (IgG4-RD). The Director, HCP Marketing will define and execute the HCP marketing strategy, ensuring the brand is optimally promoted from pre-launch through sustained post-launch performance.
This leader will partner closely with Sales, Strategic Engagement, Sales Operations, Commercial Training, and agency partners to convert customer insights into differentiated messaging, high-quality promotional assets and aligned, compliant execution. The role will also help build the marketing capabilities Zenas requires as it transitions into a fully commercial organization.